Alembic Gets Sartans Shot In Q2
Also Boosted By US Product Launches
The continuing sartans crisis and new product launches in US helped Alembic to post a strong Q2 performance, despite slowdown in other markets.
You may also be interested in...
Warning letter stemming from global nitrosamine investigation raises new concerns about Indian manufacturer.
Alembic is building up an extensive roster of solid-dose, ophthalmic and dermatological drugs to introduce in the US. With facility clearance from the FDA, the Indian firm can now target the US market for oral solids to treat cancer.
In the wake of impurities being discovered in certain valsartan and other ARB drugs, the FDA has published a list of known nitrosamine-free examples of these medicines as part of ongoing efforts to address the issue.